SCHEMBL4985347

SCHEMBL4985347

CCSc1cc(C)nc(SCC)c1NC(=O)CCCCSc1nc2ccccc2s1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
POLB P06746 2/20 0.62
MAPT P10636 3/20 0.60
ALDH1A1 P00352 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
HTT P42858 3/20 0.59
TP53 P04637 1/20 0.59
HPGD P15428 1/20 0.59
TSHR P16473 1/20 0.59
ALOX12 P18054 1/20 0.59
MAPK1 P28482 1/20 0.59
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
RECQL P46063 1/20 0.56
ATM Q13315 1/20 0.56
SOAT1 P35610 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4982610 0.99 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981691 0.99 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4988095 0.99 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981905 0.99 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4985368 0.98 LMNA (0.67) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4989291 0.88 SOAT1 (0.70) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4990028 0.88 NPC1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4987773 0.87 SOAT1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL5053929 0.87 SOAT1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL4981334 0.87 SOAT1 (0.69) LMNASMN1; SMN2POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414066-B2 Amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2008-08-19 US disclosed
US-7393866-B2 Amide compounds and medications containing the same KOWA COMPANY, LTD. (JP) 2008-07-01 US disclosed
EP-0979823-B1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2006-03-29 EP disclosed
US-20050131001-A1 Novel amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
US-20050131002-A1 Novel amide compounds and medications containing the same KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
US-6849647-B1 Amide compounds and medications containing the same technical field KOWA COMPANY, LTD. (JP) 2005-02-01 US disclosed
EP-0979823-A1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Company Ltd. (JP) 2000-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131001-A1 Novel amide compounds and medications containing the same technical field ACAT2, SULT2A1, ACAT1 LMNA 4703/4885SMN1; SMN2 2877/4885POLB 4033/4885
US-20050131002-A1 Novel amide compounds and medications containing the same ACAT2, SULT2A1, ACAT1 LMNA 4629/4885SMN1; SMN2 2534/4885POLB 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.